PNL29 ESTIMATING THE COST OF ILLNESS IN EUROPE—A MODEL WITH MULTIPLE SCLEROSIS AS AN EXAMPLE

Background Comorbidities are common among people with multiple sclerosis (PwMS); yet, their impact on the cost-of-illness (COI) in MS is unknown. Objective Explore the heterogeneity in COI trajectories among newly diagnosed PwMS in relation to type of comorbidity. Methods A nationwide longitudinal cohort study, using prospectively collected Swedish register data for seven years. The COI/year of 639 PwMS diagnosed in 2006, when aged 25–60, was estimated until 2013. Using healthcare data, PwMS were categorised into six comorbidity groups: ocular; cardiovascular, genitourinary or cancer disease; musculoskeletal; mental; neurological other than MS; and injuries. One group of PwMS without comorbidity was also created. Group-based trajectory modelling was applied, examining different COI trajectories within each comorbidity group. Results Across the seven follow-up years, PwMS with mental comorbidities had the highest COI overall (€36,482). Four COI trajectories were identified within each comorbidity group; the largest trajectory had high healthcare costs and productivity losses (36.3%–59.6% of PwMS, across all comorbidity groups). 59.6% of PwMS with mental comorbidity had high healthcare costs and productivity losses. Conclusion High COI and heterogeneity in COI trajectories could be partly explained by the presence of chronic comorbidities in the year around MS diagnosis, including the presence of mental comorbidity.

Download Full-text

Lượng giá thiệt hại chi phí sức khỏe do ô nhiễm môi trường tại làng nghề tái chế kim loại xã Văn Môn, huyện Yên Phong, tỉnh Bắc Ninh

VNU Journal of Science Economics and Business ◽

10.25073/2588-1108/vnueab.4359 ◽

2020 ◽

Vol 36 (3) ◽

Author(s):

Tien Dinh Nguyen

Keyword(s):

Cost Of Illness ◽

The Cost

Bài nghiên cứu đánh giá ảnh hưởng của việc tái chế kim loại tại làng nghề tái chế xã Văn Môn (Bắc Ninh) đến mức độ ô nhiễm môi trường, sức khỏe cộng đồng và ước tính tổn hại về kinh tế khi người dân bị bệnh do ô nhiễm môi trường gây ra. Nghiên cứu đã chỉ ra 3 nhóm bệnh chính mà người dân tại đây thường mắc phải đó là nhóm bệnh về hô hấp, nhóm bệnh về tiêu hóa và nhóm bệnh về mắt. Đặc biệt 3 nhóm bệnh này xảy ở ở độ tuổi từ 18-50 tuổi với tỷ lệ lần lượt là 18,13%; 10,78%; 12,25%. Phân tích chi phí sức khỏe (The cost of illness) cho thấy chi phí trực tiếp phải chi trả cho bệnh tật ở xã Văn Môn là 5,63 triệu đồng/hộ cao gấp 3 lần so với chi phi trực tiếp tại xã Tam Giang (1,79 triệu đồng) nơi không có hoạt động tái chế kim loại. Sử dụng mô hình hồi quy đa biến Logit đã chỉ ra các nhân tố ảnh hưởng đến xác suất mắc bệnh của người dân bao gồm vị trí nơi ở, nghề nghiệp và độ tuổi. Nghiên cứu đề xuất một số giải pháp như di dời khu tái chế kim loại ra khỏi khu dân cư, tập huấn kỹ thuật lao động cho người tham gia tái chế kim loại và nâng cao ý thức sản xuất sạch hơn nhằm giảm thiểu ô nhiễm môi trường và cải thiện sức khỏe cho người dân tại làng nghề tái chế kim loại.

Download Full-text

Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study

Healthcare ◽

10.3390/healthcare9080988 ◽

2021 ◽

Vol 9 (8) ◽

pp. 988

Author(s):

Ahmed Alghamdi ◽

Eman Algarni ◽

Bander Balkhi ◽

Abdulaziz Altowaijri ◽

Abdulaziz Alhossan

Keyword(s):

Heart Failure ◽

Saudi Arabia ◽

Cost Of Illness ◽

Economic Burden ◽

Indirect Costs ◽

Health Care Expenditures ◽

Decision Makers ◽

Hospitalization Costs ◽

Illness Study ◽

The Cost

Heart failure (HF) is considered to be a global health problem that generates a significant economic burden. Despite the growing prevalence in Saudi Arabia, the economic burden of HF is not well studied. The aim of this study was to estimate the health care expenditures associated with HF in Saudi Arabia from a social perspective. We conducted a multicenter cost of illness (COI) study in two large governmental centers in Riyadh, Saudi Arabia using 369 HF patients. A COI model was developed in order to estimate the direct medical costs associated with HF. The indirect costs of HF were estimated based on a human capital approach. Descriptive and inferential statistics were analyzed. The direct medical cost per HF patient was $9563. Hospitalization costs were the major driver in total spending, followed by medication and diagnostics costs. The cost significantly increased in line with the disease progression, ranging from $3671 in class I to $16,447 in class IV. The indirect costs per working HF patient were $4628 due to absenteeism, and $6388 due to presenteeism. The economic burden of HF is significantly high in Saudi Arabia. Decision makers need to focus on allocating resources towards strategies that prevent frequent hospitalizations and improve HF management and patient outcomes in order to lower the growing economic burden.

Download Full-text

Atherosclerosis: The cost of illness in Portugal

Revista Portuguesa de Cardiologia (English Edition) ◽

10.1016/j.repce.2020.08.003 ◽

2021 ◽

Author(s):

João Costa ◽

Joana Alarcão ◽

Alexandre Amaral‐Silva ◽

Francisco Araújo ◽

Raquel Ascenção ◽

...

Keyword(s):

Cost Of Illness ◽

The Cost

Download Full-text

The Cost of Illness of Pressure Ulcers in the Netherlands

Advances in Skin & Wound Care ◽

10.1097/00129334-200203000-00008 ◽

2002 ◽

Vol 15 (2) ◽

pp. 72-77 ◽

Cited By ~ 82

Author(s):

Johan L. Severens ◽

Jolanda M. Habraken ◽

Sanja Duivenvoorden ◽

Carla M A. Frederiks

Keyword(s):

The Netherlands ◽

Cost Of Illness ◽

Pressure Ulcers ◽

The Cost

Download Full-text

The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2019-313997 ◽

2019 ◽

Vol 104 (4) ◽

pp. 487-492 ◽

Cited By ~ 4

Author(s):

Muhammad Bayu Sasongko ◽

Firman Setya Wardhana ◽

Gandhi Anandika Febryanto ◽

Angela Nurini Agni ◽

Supanji Supanji ◽

...

Keyword(s):

Diabetic Retinopathy ◽

Laser Treatment ◽

Healthcare Cost ◽

Cost Of Illness ◽

Public Health Intervention ◽

Transportation Cost ◽

Population Based ◽

State Budget ◽

Illness Model ◽

The Cost

PurposeTo estimate the total healthcare cost associated with diabetic retinopathy (DR) in type 2 diabetes in Indonesia and its projection for 2025.MethodsA prevalence-based cost-of-illness model was constructed from previous population-based DR study. Projection for 2025 was derived from estimated diabetes population in 2025. Direct treatment costs of DR were estimated from the perspective of healthcare. Patient perspective costs were obtained from thorough interview including only transportation cost and lost of working days related to treatment. We developed four cost-of-illness models according to DR severity level, DR without necessary treatment, needing laser treatment, laser +intravitreal (IVT) injection and laser + IVT +vitrectomy. All costs were estimated in 2017 US$.ResultsThe healthcare costs of DR in Indonesia were estimated to be $2.4 billion in 2017 and $8.9 billion in 2025. The total cost in 2017 consisted of the cost for no DR and mild–moderate non-proliferative DR (NPDR) requiring eye screening ($25.9 million), severe NPDR or proliferative DR (PDR) requiring laser treatment ($0.25 billion), severe NPDR or PDR requiring both laser and IVT injection ($1.75 billion) and advance level of PDR requiring vitrectomy ($0.44 billion).ConclusionsThe estimated healthcare cost of DR in Indonesia in 2017 was considerably high, nearly 2% of the 2017 national state budget, and projected to increase significantly to more than threefold in 2025. The highest cost may incur for DR requiring both laser and IVT injection. Therefore, public health intervention to delay or prevent severe DR may substantially reduce the healthcare cost of DR in Indonesia.

Download Full-text

PND38 IMPACT of Remoteness on Cost of Illness of Australians with Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2021.04.822 ◽

2021 ◽

Vol 24 ◽

pp. S166

Author(s):

H. Ahmad ◽

der Mei I van ◽

B.V. Taylor ◽

J. Chen ◽

T. Zhao ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Of Illness

Download Full-text

A comprehensive assessment of the cost of multiple sclerosis in the United States

Multiple Sclerosis Journal ◽

10.1177/135245859800400504 ◽

1998 ◽

Vol 4 (5) ◽

pp. 419-425 ◽

Cited By ~ 125

Author(s):

Kathryn Whetten-Goldstein ◽

Frank A Sloan ◽

Larry B Goldstein ◽

Elizabeth D Kulas

Keyword(s):

Multiple Sclerosis ◽

Health Care ◽

Health Insurance ◽

Informal Care ◽

Annual Cost ◽

Lifetime Cost ◽

The United States ◽

Personal Health ◽

Secondary Sources ◽

The Cost

Comprehensive data on the costs of multiple sclerosis is sparse. We conducted a survey of 606 persons with MS who were members of the National Multiple Sclerosis Society to obtain data on their cost of personal health services, other services, equipment, and earnings. Compensation of such cost in the form of health insurance, income support, and other subsidies was measured. Survey data and data from several secondary sources was used to measure costs incurred by comparable persons without MS. Based on the 1994 data, the annual cost of MS was estimated at over $34 000 per person, translating into a conservative estimate of national annual cost of $6.8 billion, and a total lifetime cost per case of $2.2 million. Major components of cost were earnings loss and informal care. Virtually all persons with MS had health insurance, mostly Medicare/Medicaid. Health insurance covered 51 per cent of costs for services, excluding informal care. On average, compensation for earnings loss was 27 per cent. MS is very costly to the individual, health care system, and society. Much of the cost (57 per cent) is in the form of burdens other than personal health care, including earnings loss, equipment and alternations, and formal and informal care. These costs often are not calculated.

Download Full-text

Cost Analysis of Methylprednisolone Treatment of Multiple Sclerosis Patients

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ◽

10.1017/s0317167100034053 ◽

1998 ◽

Vol 25 (3) ◽

pp. 222-229 ◽

Cited By ~ 9

Author(s):

Lynda S. Robson ◽

Charlene Bain ◽

Shann Beck ◽

Suzanne Guthrie ◽

Peter C. Coyte ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Saving ◽

Cost Analysis ◽

Home Care ◽

Care Program ◽

Sensitivity Analyses ◽

Patient Treatment ◽

Fiscal Year ◽

Multiple Sclerosis Patients ◽

The Cost

ABSTRACT:Background:Intravenous methylprednisolone (IVMP) is the treatment of choice for multiple sclerosis (MS) patients undergoing acute exacerbation of disease symptoms and yet its cost has not been accurately determined. Determination of this cost in different settings is also pertinent to consideration of cost-saving alternatives to in-patient treatment.Methods:Cost analysis from the point of view of the health care system of IVMP treatment of MS patients receiving treatment in association with a selected Toronto teaching hospital in fiscal year 1994/95 was carried out. Costs of any concurrent treatments were excluded.Results:Total cost for 92 patients, based on a 4 dose regime, was estimated to be $78,527. The the cost per patient was $1,1181.84 for in-patients (IP), $714.64 for out-patients of the MS Clinic (OP) and $774.21 for patients whose treatment was initiated in the Clinic, but completed in the home (HC). Sensitivity analyses indicated: 1) IP treatment was in all cases more expensive than that of OP or HC; 2) the cost savings of OP vs. HC was sensitive to assumptions made regarding Clinic overhead, Clinic nursing costs and Home Care Program overhead.Conclusion:Alternatives to in-patient care must be considered carefully. In this study, both out-patient and in-home treatment were cost-saving alternatives to in-patient treatment, but large differences in the cost of hospital out-patient vs. in-home care could not be demonstrated.

Download Full-text